Khattak, M. A., Luke, J. J., Long, G. V., Ascierto, P. A., Rutkowski, P., Schadendorf, D., . . . Kirkwood, J. M. (2022). Adjuvant pembrolizumab versus placebo in resected high risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.

Khattak, Muhammad A., Jason J. Luke, Georgina V. Long, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Luis de la Cruz Merino, and John M. Kirkwood. Adjuvant Pembrolizumab Versus Placebo in Resected High Risk Stage II Melanoma: Health-related Quality of Life From the Randomized Phase 3 KEYNOTE-716 Study. 2022.

Khattak, Muhammad A., et al. Adjuvant Pembrolizumab Versus Placebo in Resected High Risk Stage II Melanoma: Health-related Quality of Life From the Randomized Phase 3 KEYNOTE-716 Study. 2022.